Artikelen

Oncosense Ruthenium, a drug based on protein pineapple gives very good results in first clinical trials in many cancers and is superior to cisplatin effect eg

dated September 18, 2003:
Breakthrough in treatment of various cancers (ovarian, lung, pancreas, etc.) with new cure for many cancers, and clinical trials have proven superior to cisplatin enz.te, called oncosense ruthenium, made from pineapple proteins, previously reported by University of Edinburgh dated January 2003 and the Medical Marketing International Group on the stock market today (DOW) dated September 18, 2003.

We have two press releases on this plea put in order. Interesting detail, especially the pineapple and peel of the pineapple eg pureed in a vegetarian diet as of Houtsmuller or Moerman or Gerson with lots of fruit and vegetables has long been promoted on the Internet. This new product will be very very expensive for, because with all due respect oi concerns in fighting cancer just to earn big money, but maybe a good glass of pureed pineapple a day and forget to skin, but just as good , who knows. I have not had time to translate all this, but read and make your own conclusions. Address of contact we have with MMI OPS members free.

dated September 18, 2003: Edited Press Release

LONDON (Dow Jones) - Medical Marketing International Group said Thursday thats it HAS released new information on development within-cancer therapeutics ITS wholly-owned subsidiary will, Oncosense. The new data show thats the Oncosense ruthenium compounds, discovered and patented by scientists at the University of Edinburgh and Exclusively Licensed to Oncosense, have the potential to be a whole new class of cancer therapy.
Identified the ruthenium compounds are at least as potent as the market-leading therapies carboplatin and cisplatin; WHILST offering the potential toxicity or Reduced, a novel mechanism of action, non-cross resistance and a differential spectrum of activity compared to platinum compounds.
It was Already Known That the Lead Ruthenium compounds inhibit the growth of a wide range of cancer types, eg pancreatic cancer, colon cancer and lung cancer. The new data shows That compounds have differential Their Own spectrum or activity, with individual compounds showing differential activity against individual cell lines Including non-small cell lung cancer (Which is well Known for being a Difficult to treat cancer), breast cancer and melanoma. This broad specificity supports the Data Relating to the effectiveness or ruthenium Against The tumor model resistant to the class-leading drug, cisplatin.
Preliminary studies Previously published in the British Journal of Cancer, Demonstrate higher maximum tolerated doses Can Be Achieved with ruthenium compared to cisplatin. Short-term toxicity studies for blood, kidney and liver damage, can-occure With Others Which cancer drugs are on going and Will Be Reported results in due course.
David Best, Chairman, said: "Although this is early research data, it shows Clearly the ruthenium compounds have the potential to become a leading class of cancer drugs for the future. Previously we had expected to initially develop and take forward to clinical trials the best ruthenium compound. This Has Been Encouraging greatly enhanced by the data and now we have law enforcement The Possibility of a whole series of future cancer drugs.
"If the preliminary data is CONFIRMED, with regulatory approval, We May Be Able to 'fast track' the clinical development of some of the compounds, Especially in areas where clause Currently available therapies are limited.
dated January 2003:

Potential anti-cancer properties of Ruthenium secures licensing deal for University of Edinburgh

[Edinburgh, UK - January 19, 2003], The University of Edinburgh HAS signed a worldwide exclusive licensing deal with Oncosense, a specialist in cancer therapeutics and a Wholly owned Subsidiary of Medical Marketing International Group plc (MMI), the Cambridge, UK-based technology management company listed on the London Stock Exchange (LSE: MMG), a leader in the Commercialisation of medical technologies.
The licensing deal - based on research by Professor Peter Sadler and his Colleagues within-the University's Department of Chemistry Into the anti-cancer properties of the precious metal, ruthenium - was facilitated through Blaven Technologies, MMI Group's Scottish subsidiary will based at the Alba Campus, Livingston , West Lothian.
Studies Performed in the University of Edinburgh Cancer Research Centre have Shown That Several ruthenium compounds posses anti-tumor activity against experimental tumor lines resistant to platinum-based drugs. The AIM or Professor Sadler's work is toDevelop and bring Toward clinical development, new-era ruthenium-based anti-tumor drugs and to Investigate Their mechanism of action and Their interactions with bio-molecules, Such As DNA and proteins.

Cancer Remains the second leading cause of death and as it is predominantly a disease of the elderly, the number of cases is expected to grow. The Cancer Institute USNational HAS Predicted That compromise replace cancer cardiovascular disease as the leading cause of death in the U.S. by 2003. The cancer therapeutics market was worth $ 13 billion in 2000 and is expected to double by 2005.

Platinum-based Drugs Such As cisplatin, carboplatin and oxaliplatin, are widely Used in combination therapies for numerous solid tumoren Including ovarian, lung (NSCLC, SCLC), testicular, bladder, colorectal, gastric, head and neck cancers and melanoma. Platinum Worldwide drug sales are Currently around $ 1 billion.

Cisplatin and carboplatin therapy dominate in the solid tumoren They listed above but have side effects and toxicity problems and become resistant to many solid tumoren themself. This is Where the ruthenium-based compounds May have an advantage.

MMI plans to raise the Development Funding Necessary for Oncosense to take the portfolio forward and Ruthenium Using the compromise capitalise on future licensing deal as a platform to engage with the University of Edinburgh on Further developmental work in this field.

Wendy Nicholson, Business and Commercialisation Manager, Edinburgh Research and Innovation, the University of Edinburgh's Commercialisation arm, commented, "Our alliance with MMI Injuries represents an innovative collaborative approach. It enables us to partner with one of the country's premier medical technology consultancy groups. MMI's extensification expertise and resources willing to allow early clinical development Oncosense Further explore the opportunities and thats the ruthenium Might enable portfolio.

This collaboration demonstrates the value of the University of Edinburgh's approach to the discovery and exploratory development of novel applications in biomedical research, an approach we are applying Applying Also across a number of therapeutic areas. "

Billy Mitchell, Managing Director, Blaven Technologies, added, "We Are Extremely excited by this agreement and the opportunity to collaborate with the University of Edinburgh. We are continuing to make progress in the development of new cancer therapies and the ruthenium work broadens our oncology Portfolio, Which Also includes Evaluating the potential or Other novel therapies, include MMI / ONCO 0205, for ovarian cancer. With the ruthenium license agreement in place, we can now extend the scope and pace of development in Oncosense. We look forward to Further collaborations With The University in the future and we are extremely impressed with the professionalism of the technology transfer team at Edinburgh, the whole deal was concluded in only eight weeks, a new benchmark for others and a lead universities to follow. "